Vanguard Group Inc Neurocrine Biosciences Inc Transaction History

Vanguard Group Inc

$6.44 Trillion
Q3 2025

A detailed history of Vanguard Group Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Vanguard Group Inc holds 9,706,559 shares of NBIX stock, worth $1.41 Billion. This represents 0.02% of its overall portfolio holdings.

Number of Shares

9,706,559

Previous 9,807,066 1.02%

Holding current value

$1.41 Billion

Previous $1.23 Billion 10.54%

% of portfolio

0.02%

Previous 0.02%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 07, 2025	SELL	$123.98 - $146.67 $12.5 Million - $14.7 Million	-100,507 Reduced 1.02%	9,706,559 $1.36 Billion
Q2 2025 Aug 11, 2025	SELL	$87.54 - $128.18 $11.8 Million - $17.3 Million	-134,821 Reduced 1.36%	9,807,066 $1.23 Billion
Q1 2025 May 09, 2025	SELL	$107.22 - $153.29 $19.1 Million - $27.2 Million	-177,754 Reduced 1.76%	9,941,887 $1.1 Billion
Q4 2024 Feb 11, 2025	BUY	$111.62 - $139.44 $13.7 Million - $17.1 Million	122,681 Added 1.23%	10,119,641 $1.38 Billion
Q3 2024 Nov 13, 2024	SELL	$114.58 - $153.15 $6.82 Million - $9.11 Million	-59,486 Reduced 0.59%	9,996,960 $1.15 Billion

Q2 2024 Aug 13, 2024	BUY	$130.86 - $143.19 $16.4 Million - $18 Million	125,520 Added 1.26%	10,056,446 $1.38 Billion
Q1 2024 May 10, 2024	BUY	$130.4 - $143.74 $28.8 Million - $31.7 Million	220,598 Added 2.27%	9,930,926 $1.37 Billion
Q4 2023 Feb 14, 2024	BUY	$106.07 - $132.76 $16 Million - $20 Million	150,485 Added 1.57%	9,710,328 $1.28 Billion
Q3 2023 Nov 14, 2023	SELL	$94.02 - $117.1 $1.02 Million - $1.27 Million	-10,875 Reduced 0.11%	9,559,843 $1.08 Billion
Q2 2023 Aug 14, 2023	SELL	$89.53 - $104.87 $2.4 Million - $2.81 Million	-26,814 Reduced 0.28%	9,570,718 $903 Million
Q1 2023 May 15, 2023	BUY	$94.11 - $123.02 $24.2 Million - $31.6 Million	257,237 Added 2.75%	9,597,532 $971 Million
Q4 2022 Feb 10, 2023	BUY	$106.72 - $127.06 $36.2 Million - $43.1 Million	339,332 Added 3.77%	9,340,295 $1.12 Billion
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $8.88 Million - $10.4 Million	96,489 Added 1.08%	9,000,963 $956 Million
Q2 2022 Aug 12, 2022	BUY	$75.79 - $100.07 $9.63 Million - $12.7 Million	127,016 Added 1.45%	8,904,474 $868 Million
Q1 2022 May 13, 2022	SELL	$72.45 - $94.81 $763,115 - $998,633	-10,533 Reduced 0.12%	8,777,458 $823 Million
Q4 2021 Feb 14, 2022	SELL	$79.65 - $106.22 $8 Million - $10.7 Million	-100,479 Reduced 1.13%	8,787,991 $748 Million
Q3 2021 Nov 12, 2021	SELL	$86.18 - $99.03 $8.29 Million - $9.52 Million	-96,151 Reduced 1.07%	8,888,470 $852 Million
Q2 2021 Aug 13, 2021	BUY	$89.43 - $102.27 $803 Million - $919 Million	8,984,621 New	8,984,621 $874 Million

Others Institutions Holding NBIX

# of Institutions

724

Shares Held

102M

Call Options Held

230K

Put Options Held

477K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.9B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Neurocrine Biosciences Inc Transaction History